MedPharm Ltd

Published: 4-Sep-2007
Ingredients Research & Development

Stand no: 16E58

Stand no: 16E58

MedPharm is a specialist pharmaceutical development company of international reputation, focusing in particular on topical (skin, nail, lung and other mucous membranes) drug delivery systems.

With more than 80 customers worldwide, MedPharm is recognised internationally for its unique and highly specialised service in pharmaceutical contract research and development. Services range from simple feasibility studies, dosage design and optimisation through to production of GMP clinical supplies for Phase I/II trials.

MedPharm benefits from years of commercial experience in the pharmaceutical industry, excellent project management skills and high-caliber scientific expertise.

See more

You may also like

Regulatory

TurboFil debuts latest generation of through-the-tip benchtop syringe filler

Read more
TipFil Plus provides precise, aseptic-ready filling and capping for lab and pharmacy applications

Trending Articles

  1. From powder to granules: a deep dive into wet granulation methods - WEBINAR NOW ON DEMAND Join ACG in partnership with Manufacturing Chemist for an expert-led session to explore how different wet granulation methods impact consistency, yield, and quality — and what really matters when it comes to selecting and optimising your process
  2. Orphan drug sales to exceed $400bn by 2032, Evaluate report finds Despite FDA policy shifts and the rise of blockbuster obesity drugs, a new Evaluate report confirms rare disease therapies are on track to claim more than a fifth of all global prescription drug sales within a decade
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Atrogi doses first subjects in human trial of exercise-mimicking oral therapy ATR-258 The Swedish biotech has initiated a human trial of ATR-258, a first-in-class oral β2-adrenergic receptor modulator designed to replicate the metabolic effects of exercise, including fat loss and muscle preservation, without the cardiovascular side effects associated with traditional β2-agonists
  4. Why weight sorting should move earlier in OSD development Phillip Ruda explains how earlier weight intelligence can improve process understanding, reduce risk and accelerate learning cycles
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    Moving with speed and scale: innovative, material-sparing approaches to accelerate clinical development As early-stage drug development is often hindered by limited API supply, rising costs and tight timelines, material-sparing technologies are helping companies to progress faster with less

Upcoming event

Cleanroom Technology Awards 2026

13 April | Virtual See all

You may also like

Regulatory

TurboFil debuts latest generation of through-the-tip benchtop syringe filler

TipFil Plus provides precise, aseptic-ready filling and capping for lab and pharmacy applications
Manufacturing

Concentrating recombinant proteins for drug discovery using centrifugal evaporation

Exploring purification, concentration and sample protection in recombinant protein workflows
Research & Development

COVID-19 immunity lowers the risk of a new pandemic

Researchers at the MRC-University of Glasgow Centre for Virus Research have demonstrated that the likelihood of the emergence of a new SARS-type virus pandemic has been significantly reduced by population-wide immunity to SARS-CoV-2
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Cytiva enters research partnership with SRTIGET for next-gen genomic medicine

The pair aim to expand the role of lipid nanoparticle technology into gene therapy delivery, including applications in cancer and inherited blood diseases, CNS delivery for neurological disorders where current methods fail and in vivo stem cell modification that could eliminate toxic conditioning regimens
Research & Development

Shimadzu’s Design Craftech

Fusing traditional Kyoto craft techniques with industrial production
Research & Development

Just – Evotec Biologics wins BARDA contract to optimise antibody biomanufacturing against Ebola and Sudan virus

Just – Evotec Biologics has been selected by BARDA to develop scalable, high-yield manufacturing processes for a monoclonal antibody cocktail targeting filovirus diseases under a multi-year programme valued at up to $10m
Ingredients

dsm-firmenich launches ModulaSENSE Bitter to tackle bitterness in oral drug formulations

The new taste modulation technology combines bitter blockers, maskers and sweeteners with receptor-based analysis to help pharmaceutical formulators improve the palatability of oral medicines
Subscribe now